Search the Newsreel

Cardiff Oncology (NASDAQ: CRDF) cuts R&D spend but flags going concern risk

Cardiff Oncology reported a Q2 2026 net loss of $9.2 million and a six-month operating cash outflow of $24.1 million, reducing R&D expenses by cutting clinical trials and preclinical work. The company raised $10.1 million in a direct offering but issued a "going concern" …

Concord Enviro Systems Publishes Q1 FY27 Investor Presentation

CGON (CGON) insider Ambaw Bellete plans 50,000-share stock sale

CG Oncology (CGON) insider Ambaw Bellete plans to sell 50,000 shares of common stock on August 11, 2026, through a stock option exercise settled in cash. The estimated value of this planned sale is $3,810,255.00. This disclosure also reveals several recent sales of CGON …

Cardiff Oncology earnings missed by $0.02, revenue topped estimates

Cardiff Oncology: Q2 Earnings Snapshot

Cardiff Oncology, Inc. (CRDF) reported a Q2 loss of $9.2 million, or 14 cents per share, surpassing Wall Street expectations that predicted a loss of 17 cents per share. The company achieved revenue of $104,000, which met Street forecasts. This financial summary was generated …

Two July Hires Receive Options on 65,350 BridgeBio Shares

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced it granted inducement equity awards on August 10, 2026, to two new employees hired in July 2026. These employees received non-qualified stock options for an aggregate of 65,350 shares of common stock at an exercise price of $9.28 …

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics (BBOT) announced inducement grants of non-qualified stock options to two new employees hired in July 2026. These grants, totaling 65,350 shares at an exercise price of $9.28 per share, were made under BBOT’s 2025 Inducement Plan and approved in accordance with …

Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS

Cardiff Oncology (NASDAQ:CRDF) reported a quarterly loss of $0.14 per share, missing analyst expectations by $0.02, despite revenue of $0.10 million surpassing the consensus estimate. The company's shares are trading under pressure, well below moving averages, and analysts generally hold a "Hold" rating. Despite …

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Cardiff Oncology announced its second quarter 2026 financial results and provided a business update, highlighting positive Phase 2 data for its drug onvansertib in first-line RAS-mutated metastatic colorectal cancer. The company plans to initiate a registrational Phase 3 trial in Q1 2027, pending additional …

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) doubles R&D spend, logs $98.6M loss

Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com

Cullinan Oncology (CGEM) stock has reached a new 52-week high of $19.43, reflecting a substantial increase of approximately 158% over the past year. The company's market capitalization now stands at $1.24 billion, driven by strong investor confidence and recent positive developments. These include favorable …

CG Oncology (NASDAQ:CGON) Hits New 52-Week High - Should You Buy?

CG Oncology (NASDAQ:CGON) recently reached a new 52-week high of $77.49, with a current trading price near $76.98. The clinical-stage biopharmaceutical company has a "Moderate Buy" consensus rating from analysts, with several price target increases, but reported a quarterly loss of $0.90 per share, …

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ALX Oncology Holdings Inc. (ALXO) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to …

Concord Healthcare Schedules Board Meeting to Review Interim Results and Dividend

Citius Oncology (CTOR) Expected to Announce Earnings on Tuesday

Citius Oncology (NASDAQ:CTOR) is anticipated to release its Q3 2026 earnings before market open on Tuesday, August 18th, with analysts forecasting a loss of $0.04 per share and revenue of $5.83 million. The upcoming earnings call is scheduled for August 21st. The company's previous …

ALX Oncology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

ALX Oncology Holdings Inc has released its earnings summary for the quarter that ended on June 30. The article is a brief announcement of these results, directing readers to access the full report on TradingView, which aggregates content from Reuters and other news sources.

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

Kura Oncology announced the publication of a manuscript in Blood detailing the discovery and preclinical development of ziftomenib, a menin inhibitor approved by the FDA for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The publication highlights ziftomenib's differentiated binding profile, potent and selective …

Concord Enviro posts ₹175.69 cr Q1FY27 loss; appoints new CFO

Concord New Energy expects H1 profit to fall over 66% on drop in power generation

CGON (CGON) insider plans 50,000-share stock sale after option exercise

CG Oncology, Inc. (CGON) filed a Form 144 indicating an insider's plan to sell 50,000 shares of common stock, valued at $3,770,580.00, on August 10, 2026, following a stock option exercise. The filing also details previous common stock sales by Ambaw Bellete over the …

Kura Oncology publishes preclinical data on ziftomenib in Blood By Investing.com

Kura Oncology has published preclinical data in Blood journal detailing the discovery and development of ziftomenib, a menin inhibitor approved by the FDA in 2025 for adult patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The research highlights ziftomenib's efficacy across various leukemia …

Kura Oncology publishes study highlighting ziftomenib's unique action and potential in treating acute leukemias.

Kura Oncology announced the publication of a study in the journal Blood detailing the discovery and preclinical development of ziftomenib, an FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The study highlights ziftomenib's potent and selective inhibition of the menin-KMT2A …

Dimensional Fund Advisors LP Increases Holdings in Kura Oncology, Inc. $KURA

Dimensional Fund Advisors LP significantly increased its stake in Kura Oncology, Inc. by 32.3% in the first quarter, now holding 1.43 million shares valued at $11.6 million. Other institutions also grew their positions, while an insider sold shares. Analysts maintain a "Moderate Buy" rating …

Hennion & Walsh Asset Management Inc. Grows Stake in Kura Oncology, Inc. $KURA

Hennion & Walsh Asset Management Inc. significantly increased its stake in Kura Oncology (NASDAQ:KURA) by 69.7% in Q2, bringing its total holdings to 568,845 shares valued at $6.24 million. Despite reporting a quarterly loss that beat estimates, revenue fell short, and an insider recently …

Concord New Energy flags sharp interim profit drop on weaker power output

Concord New Energy Sets Board Meeting to Approve Interim Results and Dividend

Pyxis Oncology Inc expected to post a loss of 35 cents a share - Earnings Preview

Pyxis Oncology Inc is projected to report a loss of 35 cents per share, according to an earnings preview. This information suggests an upcoming financial disclosure for the company. The full article is available to subscribers of TradingView.

(CGEM) Movement as an Input in Quant Signal Sets

This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models to generate trading strategies. It highlights a strong near-term sentiment possibly leading to a long-term positive bias, with support being tested. The analysis provides specific entry, target, and stop-loss levels for position, momentum …

Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Bank of America Securities Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON)

Bank of America Securities reiterated a Buy rating on CG Oncology, Inc. (CGON) with an $88.00 price target. This affirmation follows the company's Q2 earnings report, which showed $1.16 million in revenue and a net profit of $0, a significant improvement from the prior …

Concord Medical Services Holdings Ltd. ADR Revenue Breakdown – FWB:C2C

This article provides a brief overview of Concord Medical Services Holdings Ltd. ADR (FWB:C2C) revenue breakdown, highlighting that its greatest contribution came from China. In the last year, China accounted for 54.54 million EUR, which was an increase from 51.54 million EUR the year …

BridgeBio Oncology Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.89, Implies 167% Upside

BridgeBio Oncology Therapeutics, Inc. (BBOT) has seen its average 12-month price target cut slightly from $25.3 to $24.89 by 9 analysts. This new target still implies a significant 167% potential upside from its August 7th closing price. The consensus rating from 10 covering analysts …

Enterprise value to EBITDA forward of CG Oncology, Inc. – NASDAQ:CGON

This page from TradingView provides financial information for CG Oncology, Inc. (NASDAQ: CGON), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed at the time of viewing and presents various navigation options related to markets, products, and …

Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates

Oncolytics Biotech Inc (ONCY) has an earnings forecast score of 7.67, ranking 274 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $5.25 for ONCY, with a high of $10.00 and a low of $3.00, …

Pyxis Oncology Inc (PYXS) Stock News Today

This article from TradingKey provides current stock news for Pyxis Oncology Inc (PYXS). It lists the company's stock price, market capitalization, and indicates that more news, earnings, and analyst ratings will be updated soon. The content serves as a placeholder for ongoing updates regarding …

CG Oncology (NASDAQ:CGON) Posts Earnings Results, Misses Expectations By $0.24 EPS

CG Oncology (NASDAQ:CGON) reported a wider-than-expected quarterly loss of $0.90 per share, missing consensus estimates by $0.24, despite revenue of $1.16 million surpassing expectations. The stock saw a slight increase to $75.10, near its 52-week high, and maintains a "Moderate Buy" consensus rating with …